Hepatic injury caused by benzbromarone.
This case study describes a woman who developed a predominantly hepatocellular injury, approximately 3 months after starting treatment with 100 mg benzbromarone daily. She had also taken 250 mg methyldopa daily for several years. Infections with hepatitis A and B were excluded serologically, no autoantibodies were demonstrated, and ultrasonography and endoscopic retrograde cholangiopancreatography did not show extrahepatic obstruction. The patient recovered after discontinuation of both drugs. Two years later, readministration of benzbromarone was followed by a relapse. Later, methyldopa was used without problems. We conclude that hepatic injury in this patient was caused by benzbromarone.
Department of Internal Medicine II, University Hospital Dijkzigt, Rotterdam, The Netherlands.
M M
MM
van der Klauw
P M
PM
Houtman
B H
BH
Stricker
P
P
Spoelstra
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001553:Benzbromarone / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D006042:Goiter / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D008107:Liver Diseases / Q000097:blood / Q000503:physiopathology
D001553:Benzbromarone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase